These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12871368)

  • 1. Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis.
    Sarich TC; Osende JI; Eriksson UG; Fager GB; Eriksson-Lepkowska M; Ohlsson L; Carlsson S; Wåhlander K; Gustafsson D; Badimon JJ
    J Thromb Haemost; 2003 May; 1(5):999-1004. PubMed ID: 12871368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
    Sarich TC; Wolzt M; Eriksson UG; Mattsson C; Schmidt A; Elg S; Andersson M; Wollbratt M; Fager G; Gustafsson D
    J Am Coll Cardiol; 2003 Feb; 41(4):557-64. PubMed ID: 12598065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
    Wåhlander K; Eriksson-Lepkowska M; Nyström P; Eriksson UG; Sarich TC; Badimon JJ; Kalies I; Elg M; Bylock A
    Thromb Haemost; 2006 Mar; 95(3):447-53. PubMed ID: 16525572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
    Boström SL; Hansson GF; Sarich TC; Wolzt M
    Thromb Res; 2004; 113(1):85-91. PubMed ID: 15081569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
    Carlsson S; Elg M; Mattsson C
    Thromb Res; 2002 Aug; 107(3-4):163-8. PubMed ID: 12431484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.
    Bossavy JP; Sakariassen KS; Rübsamen K; Thalamas C; Boneu B; Cadroy Y
    Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1348-53. PubMed ID: 10323789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of the oral direct thrombin inhibitor ximelagatran.
    Mattsson C; Sarich TC; Carlsson SC
    Semin Vasc Med; 2005 Aug; 5(3):235-44. PubMed ID: 16123910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Johansson LC; Frison L; Logren U; Fager G; Gustafsson D; Eriksson UG
    Clin Pharmacokinet; 2003; 42(4):381-92. PubMed ID: 12648028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.
    Wåhlander K; Lapidus L; Olsson CG; Thuresson A; Eriksson UG; Larson G; Eriksson H
    Thromb Res; 2002 Aug; 107(3-4):93-9. PubMed ID: 12431473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
    Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
    Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.
    Gustafsson D; Elg M
    Thromb Res; 2003 Jul; 109 Suppl 1():S9-15. PubMed ID: 12818629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatran.
    Wernevik LC; Nyström P; Andersson M; Johnsson G; Bylock A; Nakanishi T; Eriksson UG
    Clin Pharmacokinet; 2006; 45(1):85-94. PubMed ID: 16430313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation.
    Wolzt M; Boström SL; Svensson M; Wåhlander K; Grind M; Sarich TC
    Pathophysiol Haemost Thromb; 2003; 33(2):68-74. PubMed ID: 14624047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The new antithrombotic agents].
    Meyer Samama M
    Presse Med; 2005 Oct; 34(18):1309-14. PubMed ID: 16269995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
    Agnelli G; Renga C; Weitz JI; Nenci GG; Hirsh J
    Blood; 1992 Aug; 80(4):960-5. PubMed ID: 1498336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
    Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
    Mehta JL; Chen L; Nichols WW; Mattsson C; Gustafsson D; Saldeen TG
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):345-51. PubMed ID: 9514177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting.
    Bode C; Hanson SR; Schmedtje JF; Haber E; Mehwald P; Kelly AB; Harker LA; Runge MS
    Circulation; 1997 Feb; 95(4):800-4. PubMed ID: 9054733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.